Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, BioNTech SE ADR (NASDAQ: BNTX) closed at $104.51 up 2.25% from its previous closing price of $102.21. In other words, the price has increased by $2.25 from its previous closing price. On the day, 0.56 million shares were traded. BNTX stock price reached its highest trading level at $104.74 during the session, while it also had its lowest trading level at $101.8.
Ratios:
For a deeper understanding of BioNTech SE ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.48 and its Current Ratio is at 8.61. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 05, 2025, Reiterated its Buy rating but revised its target price to $145 from $134 previously.
On May 29, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $110.
On March 13, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $145.Citigroup initiated its Buy rating on March 13, 2025, with a $145 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 05 ’25 when ATHOS KG bought 500,000 shares for $112.46 per share.
Medine GmbH bought 1,774,837 shares of BNTX for $200,024,130 on Aug 15 ’25. On Aug 15 ’25, another insider, Tureci Ozlem, who serves as the Officer of the company, bought 185,001 shares for $112.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNTX now has a Market Capitalization of 25124071424 and an Enterprise Value of 11356971008. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.04 while its Price-to-Book (P/B) ratio in mrq is 1.16. Its current Enterprise Value per Revenue stands at 3.946 whereas that against EBITDA is -23.004.
Stock Price History:
The Beta on a monthly basis for BNTX is 1.54, which has changed by -0.1481089 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, BNTX has reached a high of $129.27, while it has fallen to a 52-week low of $81.20. The 50-Day Moving Average of the stock is -0.91%, while the 200-Day Moving Average is calculated to be -2.32%.
Shares Statistics:
For the past three months, BNTX has traded an average of 882.82K shares per day and 826940 over the past ten days. A total of 240.40M shares are outstanding, with a floating share count of 236.74M. Insiders hold about 1.52% of the company’s shares, while institutions hold 21.90% stake in the company. Shares short for BNTX as of 1757894400 were 6378629 with a Short Ratio of 7.23, compared to 1755216000 on 6315487. Therefore, it implies a Short% of Shares Outstanding of 6378629 and a Short% of Float of 6.909999999999999.
Earnings Estimates
BioNTech SE ADR (BNTX) is currently under the scrutiny of 15.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.96, with high estimates of $0.6 and low estimates of -$3.51.
Analysts are recommending an EPS of between $1.59 and -$7.68 for the fiscal current year, implying an average EPS of -$4.05. EPS for the following year is -$3.69, with 20.0 analysts recommending between $1.05 and -$7.85.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $1.03B this quarter.It ranges from a high estimate of $2.13B to a low estimate of $542.4M. As of. The current estimate, BioNTech SE ADR’s year-ago sales were $1.24BFor the next quarter, 12 analysts are estimating revenue of $963.17M. There is a high estimate of $1.15B for the next quarter, whereas the lowest estimate is $721M.
A total of 19 analysts have provided revenue estimates for BNTX’s current fiscal year. The highest revenue estimate was $4.2B, while the lowest revenue estimate was $1.61B, resulting in an average revenue estimate of $2.4B. In the same quarter a year ago, actual revenue was $2.75BBased on 18 analysts’ estimates, the company’s revenue will be $2.49B in the next fiscal year. The high estimate is $3.55B and the low estimate is $1.58B.
